August Troendle - Coherus BioSciences Director
| CHRS Stock | USD 2.02 0.16 7.34% |
Director
Dr. August J. Troendle, M.D., is Director of the Company. Dr. Troendle was the Chief Executive Officer, President and Chairman of Medpace, Inc., a clinical research organization, since its inception in 1992. Dr. Troendle previously worked for Sandoz where he was responsible for the clinical development of lipid altering agents. His experience as Medical Review Officer in the Division of Metabolic and Endocrine Drug Products at the FDA gives him insight into the regulatory environment for the development of drugs in the metabolic and cardiovascular fields. He also formerly served on the board of directors of Xenon Pharmaceuticals Inc. from 2009 to 2010. Dr. Troendle received his M.D. from the University of Maryland, School of Medicine. since 2011.
| Age | 59 |
| Tenure | 13 years |
| Address | 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 |
| Phone | 650 649 3530 |
| Web | https://www.coherus.com |
August Troendle Latest Insider Activity
Tracking and analyzing the buying and selling activities of August Troendle against Coherus BioSciences stock is an integral part of due diligence when investing in Coherus BioSciences. August Troendle insider activity provides valuable insight into whether Coherus BioSciences is net buyers or sellers over its current business cycle. Note, Coherus BioSciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Coherus BioSciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
August Troendle over two months ago Disposition of 13988 shares by August Troendle of Medpace Holdings at 386. subject to Rule 16b-3 | ||
August Troendle over two months ago Disposition of 50000 shares by August Troendle of Medpace Holdings at 1.75 subject to Rule 16b-3 | ||
August Troendle over three months ago Sale by August Troendle of 3167 shares of Medpace Holdings | ||
August Troendle over three months ago Sale by August Troendle of 25000 shares of Medpace Holdings |
Coherus BioSciences Management Efficiency
The company has return on total asset (ROA) of (0.2175) % which means that it has lost $0.2175 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.5706) %, meaning that it created substantial loss on money invested by shareholders. Coherus BioSciences' management efficiency ratios could be used to measure how well Coherus BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.97 in 2024, whereas Return On Tangible Assets are likely to drop (0.45) in 2024. At this time, Coherus BioSciences' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 74.4 M in 2024, whereas Total Current Assets are likely to drop slightly above 311.1 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Cynthia Smith | Spero Therapeutics | 49 | |
| Rina Shafir | Bolt Biotherapeutics | 50 | |
| Paul Newfield | Instil Bio | N/A | |
| Tridibesh Mukherjee | Instil Bio | 74 | |
| Alfredo Gusman | Bolt Biotherapeutics | N/A | |
| Matthew Young | CytomX Therapeutics | 49 | |
| Patricia Tilton | Instil Bio | N/A | |
| JeanFranois Formela | Spero Therapeutics | 61 | |
| Ervin Wijaya | Bolt Biotherapeutics | 56 | |
| Phillip Strachan | Instil Bio | N/A | |
| Anibal Bernardo | Bolt Biotherapeutics | N/A | |
| Mark Auerbach | Assembly Biosciences | 78 | |
| Roger Loeb | Instil Bio | N/A | |
| Iwan Harianto | Bolt Biotherapeutics | 62 | |
| Eliahu Shohet | Bolt Biotherapeutics | 56 | |
| John Pottage | Spero Therapeutics | N/A | |
| Jran Zhang | Bolt Biotherapeutics | 49 | |
| Manju Mazumder | Instil Bio | N/A | |
| Geoffrey Swier | Instil Bio | N/A | |
| Marion McCourt | CytomX Therapeutics | 58 | |
| Vimal Vallabh | Instil Bio | N/A | |
Management Performance
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.22 |
Coherus BioSciences Leadership Team
Elected by the shareholders, the Coherus BioSciences' board of directors comprises two types of representatives: Coherus BioSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coherus. The board's role is to monitor Coherus BioSciences' management team and ensure that shareholders' interests are well served. Coherus BioSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coherus BioSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vladimir Vexler, Chief Scientific Officer | ||
| Bryan Mcmichael, Principal Accounting | ||
| Dennis Lanfear, Chairman, CEO and Pres | ||
| Mats Wahlstrom, Independent Director | ||
| Alan Herman, Chief Scientific Officer | ||
| Rebecca Sunshine, Chief Officer | ||
| Thomas Fitzpatrick, Chief Legal Officer | ||
| Mary Szela, Independent Director | ||
| Karen Kotz, Ex Accounts | ||
| Jami Taylor, Vice Relations | ||
| Christopher Slavinsky, Chief Officer | ||
| Cheston Turbyfill, Vice Communications | ||
| Ali Satvat, Independent Director | ||
| McDavid Stilwell, Chief Officer | ||
| Paul Reider, Chief Officer | ||
| Peter Watler, Chief Technical Officer | ||
| James Daly, Executive Chairman of the Board | ||
| Samuel Nussbaum, Director | ||
| Christos Richards, Director | ||
| August Troendle, Director | ||
| James Healy, Independent Director | ||
| Michael Chen, Senior Trade | ||
| Theresa Lavallee, Chief Board | ||
| MRCP MD, Chief Officer | ||
| Scott Saywell, Executive Development | ||
| Bryan Lawlis, Independent Director | ||
| JeanFrederic Viret, CFO | ||
| Barbara Finck, Chief Medical Officer | ||
| Darlene Horton, Chief Medical and Regulatory Affairs Officer | ||
| Vincent Anicetti, Chief Quality and Compliance Officer | ||
| Richard Hameister, Chief Officer |
Coherus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Coherus BioSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.92) % | ||||
| Operating Margin | (0.99) % | ||||
| Current Valuation | 608.81 M | ||||
| Shares Outstanding | 113.5 M | ||||
| Shares Owned By Insiders | 1.40 % | ||||
| Shares Owned By Institutions | 77.40 % | ||||
| Number Of Shares Shorted | 23.45 M | ||||
| Price To Earning | 4.22 X |
Pair Trading with Coherus BioSciences
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Coherus BioSciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Coherus BioSciences will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Coherus BioSciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Coherus BioSciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Coherus BioSciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Coherus BioSciences to buy it.
The correlation of Coherus BioSciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Coherus BioSciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Coherus BioSciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Coherus BioSciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Coherus BioSciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Coherus Stock please use our How to Invest in Coherus BioSciences guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Coherus Stock analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Coherus BioSciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Coherus BioSciences. If investors know Coherus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Coherus BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (2.53) | Revenue Per Share 2.732 | Quarterly Revenue Growth 1.018 | Return On Assets (0.22) |
The market value of Coherus BioSciences is measured differently than its book value, which is the value of Coherus that is recorded on the company's balance sheet. Investors also form their own opinion of Coherus BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Coherus BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Coherus BioSciences' market value can be influenced by many factors that don't directly affect Coherus BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Coherus BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Coherus BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Coherus BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.